

Appl. No. 10/076,248
Reply to Office action of August 2, 2005
Response dated January 30, 2006

JAN 31 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/076,248 Confirmation No.: 6317
Applicant. : MITCHELL et al.
Filed : February 12, 2002
TC/A.U. : 1637
Examiner : Cynthia B. Wilder
Docket No. : 027705.00004
Customer No. : 38485
For : METHODS AND COMPOSITIONS FOR USE IN SPLICEOSOME
MEDIATED RNA *TRANS*-SPLICING

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TERMINAL DISCLAIMER PURSUANT TO 37 C.F.R. 37 C.F.R. 1.321(c)

Sir:

Intron, Inc., the owner of the entire interest in U.S. Application Serial No. 10/076,248 filed on February 12, 2002 entitled "METHODS AND COMPOSITIONS FOR USE IN SPLICEOSOME MEDIATED RNA *TRANS*-SPLICING", which claims priority to provisional application number 60/008,717, filed on December 15, 1995 and is a continuation-in-part of U.S. Patent Application Serial No. 08/766,354, filed on December 13, 1996, now U.S. Patent No. 6,013,487, which is a continuation-in-part of U.S. Patent Application Serial No. 09/087,233, filed on May 28, 1998 (abandoned), which is a continuation-in-part of U.S. Patent Application Serial No. 09/133,717, filed on August 13, 1998, now U.S. Patent No. 6,083,702, which is a continuation-in-part of U.S.

NYC/250256.1

1

02/01/2006 MBINAS 00000012 10076248

01 FC:2814

65.00 OP

Appl. No. 10/076,248
Reply to Office action of August 2, 2005
Response dated January 30, 2006

Patent Application Serial No. 09/158,863, filed on September 23, 1998, now U.S. Patent No. 6,280,978, which is a continuation-in-part of U.S. Patent Application Serial No. 09/756,096, filed on January 8, 2001, which is a continuation-in-part of U.S. Patent Application Serial No. 09/838,858, filed on April 20, 2001, which is a continuation-in-part of U.S. Patent Application Serial No. 09/941,492, filed on August 29, 2001, as evidenced by an assignment to Intronn, Inc., which has been recorded in the U.S. Patent and Trademark Office on July 30, 2002 at Reel number 013136 and Frame number 0119, hereby disclaims the terminal part of the statutory term of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term, defined in 35 U.S.C. § 154 to 156 and 173, of commonly owned issued U.S. Patent Nos. 6,013,487; 6,083,702; and 6,280,978. The owners hereby agree that any patent so granted on the above-identified application shall be enforceable only for and during such period that the above-identified applications and granted U.S. Patent Nos. 6,013,487; 6,083,702; and 6,280,978 are commonly owned. In addition, Intronn, Inc., hereby disclaims the terminal part of the statutory term of any patent granted on the above-identified application, which would extend beyond the expiration date of any patent granted from U.S. Patent Application No. 09/756,096, U.S. Patent Application No. 09/941,492, U.S. Patent Application No. 09/838,858 and U.S. Patent Application No. 10/456,153. The owners hereby agree that any patent so granted on the above-identified application shall be enforceable only for and during such period that the above-identified applications and any patent granted from U.S. Patent Application No. 09/756,096, U.S.

Appl. No. 10/076,248
Reply to Office action of August 2, 2005
Response dated January 30, 2006

Patent Application No. 09/941,492, U.S. Patent Application No. 09/838,858 and U.S.
Patent Application No. 10/456,153 are commonly owned.

This agreement shall run with any patent granted on the instant application and
shall be binding upon the assignees, their successors, or assigns.


The undersigned is attorney of record and has the authority to execute this
Terminal Disclaimer on behalf of Intronn, Inc., and has reviewed the above-referenced
assignments and hereby certifies that, to the best of my knowledge and belief, title is in
the assignees on whose behalf this terminal disclaimer is being filed.

I hereby declare that all statements made herein of my own knowledge are true
and that all statements made on information and belief are believed to be true; and further
that these statements were made with the knowledge that willful false statements and the
like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title
18 of the United States Code and that such willful false statements may jeopardize the
validity of the application or any patent issued thereon.

Appl. No. 10/076,248
Reply to Office action of August 2, 2005
Response dated January 30, 2006

Payment of the filing fee in the amount of \$65.00, pursuant to 37 C.F.R. §1.20 (d), is to be made according to the Credit Card Payment Form attached herewith. Applicants believe that no additional fees are required in connection with this filing. However, if additional fees are required, the Commissioner is hereby authorized to charge any additional payment, or credit any overpayment, to Deposit Account No. 01-2300, referencing Docket Number 027705.00004.

Respectfully submitted,



Rochelle K. Seide, Ph.D.
Registration No. 32,300
ARENT FOX PLLC
1675 Broadway
New York, NY 10019
Tel. No. (212) 484-3945
Fax No. (212) 484-3990
Customer No. 38485